At a glance
- Originator Abbott Laboratories
- Developer Abbott Laboratories; ICOS Corporation
- Class
- Mechanism of Action E-selectin inhibitors; Intercellular adhesion molecule 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 15 May 2001 Discontinued-Preclinical for Inflammation in USA (PO)
- 15 Sep 1999 Preclinical development for Inflammation in USA (PO)